Johnson & Johnson vs Kia: Revenue, Profit and Business Model
Johnson & Johnson reported $94.2B of revenue in FY2025 and $26.8B of net income. Kia reported ~$81B of revenue in FY2025 and ~$5.4B of net income.
Latest financial snapshot
Johnson & Johnson
- Latest revenue
- $94.2B (FY2025)
- Net income
- $26.8B
- Net margin
- 28.5%
- Revenue growth
- +3.0% a year, FY2016–FY2025
Kia
- Latest revenue
- ~$81B (FY2025)
- Net income
- ~$5.4B
- Net margin
- 6.6%
- Revenue growth
- +13.1% a year, FY2021–FY2025
Financial summary
Johnson & Johnson
J&J's sales grew from $85.2 billion in 2023 to $88.8 billion in 2024 and $94.2 billion in 2025, while FY2025 net earnings reached $26.8 billion. Q2 2026 sales were $25.31 billion (Innovative Medicine $16.38 billion, MedTech $8.93 billion), net earnings were $5.53 billion, adjusted EPS was $2.90, and first-half free cash flow was about $8.7 billion. Management guides 2026 sales of $100.8 to $101.4 billion and adjusted EPS of $11.60 to $11.75. The company has raised its dividend for more than 60 consecutive years, and its market value was roughly $644 billion in mid-September 2026.
Kia
Kia's revenue has risen every year since 2020: from ~$49.6 billion (KRW 69.9 trillion) in 2021 to ~$76.3 billion (KRW 107.4 trillion) in 2024 and a record ~$81 billion (KRW 114.1 trillion) in 2025 (+6.2%). Profit has not kept up. Operating profit fell 28.3% in 2025 to ~$6.45 billion (KRW 9.08 trillion), and the margin dropped from 11.8% to 8.0% as US tariffs and incentives ate into earnings. Net profit was about $5.36 billion (KRW 7.55 trillion). The squeeze continued into 2026. Q1 revenue was a record ~$20.9 billion (KRW 29.50 trillion) (+5.3%), but operating profit fell 26.7% to ~$1.57 billion (KRW 2.21 trillion). Q2 revenue reached ~$23.5 billion (KRW 33.04 trillion) (+12.6%) while operating profit fell 4.9% to ~$1.87 billion (KRW 2.63 trillion). The shares dropped about 13% on the day of the Q2 results. Shareholder returns are still high: the 2025 dividend was KRW 6,800 per share, a 35% consolidated payout ratio, and Kia has been cancelling treasury shares, cutting issued shares from 405.4 million in 2022 to 390.4 million at the end of 2025.
Revenue and profit by year
Johnson & Johnson
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $94.2B | $26.8B | 28.5% | +6.0% | Source |
| FY2024 | $88.8B | $14.1B | 15.8% | +4.3% | Source |
| FY2023 | $85.2B | $35.2B | 41.3% | +6.5% | Source |
| FY2022 | $80B | $17.9B | 22.4% | +1.6% | Source |
| FY2021 | $78.7B | $20.9B | 26.5% | -4.7% | Source |
| FY2020 | $82.6B | $14.7B | 17.8% | +0.6% | Source |
| FY2019 | $82.1B | $15.1B | 18.4% | +0.6% | Source |
| FY2018 | $81.6B | $15.3B | 18.8% | +6.7% | Source |
| FY2017 | $76.5B | $1.3B | 1.7% | +6.3% | Source |
| FY2016 | $71.9B | $16.5B | 23.0% | — | Source |
Where the revenue comes from
Johnson & Johnson
- Innovative Medicine~64%
Innovative Medicine generated $60.401 billion in FY2025 sales across oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism.
- MedTech~36%
MedTech generated $33.792 billion in FY2025 sales across surgery, orthopaedics, cardiovascular, and vision products.
Kia
- Global Vehicle Sales
primary revenue source
Kia generates most revenue from selling SUVs, passenger cars, hybrids, EVs, and commercial vehicles through regional subsidiaries, importers, dealers, and fleet channels.
- Parts, Service, and Accessories
recurring support revenue
Genuine parts, aftersales service, accessories, and warranty-related activity provide higher-repeat revenue tied to Kia's installed vehicle base.
- Future Mobility and PBVs
emerging growth area
Dedicated EVs, software-defined vehicles, purpose-built vehicles, and connected services support Kia's longer-term mobility strategy.
Business model and strategy
Johnson & Johnson
How it makes money
J&J makes money in two ways. Innovative Medicine (about 64% of FY2025 sales, $60.4 billion) sells patented prescription medicines to wholesalers, specialty pharmacies, hospitals, and governments; key products include DARZALEX for multiple myeloma, TREMFYA and STELARA in immunology, ERLEADA in prostate cancer, CARVYKTI cell therapy, and CAPLYTA, added through the 2025 Intra-Cellular Therapies deal.
Growth strategy
J&J is narrowing its portfolio toward higher-growth areas. It spun off consumer health as Kenvue in 2023, announced in October 2025 that it will separate its orthopaedics business as DePuy Synthes, and used acquisitions to refill its pipeline: Abiomed ($16.6 billion, 2022), Shockwave Medical ($13.1 billion, 2024), and Intra-Cellular Therapies ($14.6 billion, 2025).
Competitive advantage
J&J's edge is breadth plus balance-sheet strength. It runs one of the largest pharmaceutical R&D budgets in the industry, holds a AAA credit rating from S&P (one of only two US companies with that rating, alongside Microsoft), and sells into hospitals across pharmaceuticals and devices at the same time.
Kia
How it makes money
Kia makes money mainly by building and selling vehicles wholesale to its regional sales subsidiaries, importers and franchised dealers, which then sell to retail and fleet buyers. SUVs and RVs such as the Sportage, Sorento, Seltos, Carnival and Telluride make up most of the mix and earn more per unit than small sedans.
Growth strategy
Kia's current strategy, set out at the 2026 CEO Investor Day, uses several powertrains instead of only EVs. It plans to grow EVs (EV3, EV4, EV5, EV6, EV9 and later models) and hybrids together, add a PBV line of modular electric vans starting with the PV5, and build up software-defined vehicles, autonomous driving and robotics as longer-term businesses.
Competitive advantage
Kia's main advantages are its scale inside Hyundai Motor Group and the way it can switch powertrains easily. Sharing platforms, the E-GMP 800V EV architecture, batteries, chips and logistics (Hyundai Glovis) with Hyundai lowers development and purchasing costs. Factories in Korea, the US (Georgia), Mexico, Slovakia and India let Kia shift production between combustion, hybrid and electric models.
Questions about Johnson & Johnson vs Kia
Which company has higher revenue — Johnson & Johnson or Kia Corporation?
Johnson & Johnson reported $94.2B (FY2025), while Kia Corporation reported ~$81B (FY2025). By last reported revenue, Johnson & Johnson is the larger business, with Kia Corporation reporting a smaller revenue base.
What is the market cap of Johnson & Johnson vs Kia Corporation?
Johnson & Johnson's market capitalisation stands at $643.9B, while Kia Corporation's is $32.4B. Johnson & Johnson carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Kia Corporation.
Which is more financially efficient — Johnson & Johnson or Kia Corporation?
Johnson & Johnson generates $669k / employee in revenue per employee, while Kia Corporation generates $1.52M / employee. Kia Corporation shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do Johnson & Johnson and Kia Corporation make money?
Johnson & Johnson and Kia Corporation generate revenue in fundamentally different ways. Johnson & Johnson: J&J makes money in two ways. Kia Corporation: Kia makes money mainly by building and selling vehicles wholesale to its regional sales subsidiaries, importers and franchised dealers, which then sell to retail and fleet buyers.
Which company is valued higher relative to revenue — Johnson & Johnson or Kia Corporation?
On a price-to-sales (P/S) basis, Johnson & Johnson trades at 6.8x P/S and Kia Corporation at 0.4x P/S. Johnson & Johnson commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Kia Corporation. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Johnson & Johnson bigger than Kia Corporation?
By last reported revenue, Johnson & Johnson ($94.2B (FY2025)) is the larger company compared to Kia Corporation (~$81B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Johnson & Johnson vs Kia overview